Regulation of B Cell Development and Function by Zfp521

Zfp521 对 B 细胞发育和功能的调节

基本信息

  • 批准号:
    8401781
  • 负责人:
  • 金额:
    $ 40.73万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-03 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Summary B cell development in the bone marrow proceeds in a stepwise process from multipotent hematopoietic stem cells (HSCs) to committed immature B lymphocytes. Research has elucidated a B cell-specific regulatory network of transcription factors necessary for the development of early B cells. These proteins include Early B cell Factor 1 (EBF1), which drives B lineage specification and commitment. Although much is known about EBF1, there are many unanswered questions concerning its regulation in B cells and its potential for protein- protein interactions. Several lines of evidence point to Zfp521 (Evi3/ZNF521/EHZF) as a co-regulator of gene transcription with EBF1. Zfp521 interacts physically with EBF1 and can repress its activity in vitro. Zfp521 is co- expressed with EBF1 in developing B cells. However, little is known concerning functions of Zfp521 in B cell development. Specifically, the mechanisms by which Zfp521 modulates activities of EBF1 and the basis and consequences of physical interactions between Zfp521 and EBF1 are unknown. We have demonstrated that early B cell development is perturbed greatly in the absence of Zfp521. This is evidenced by a lack of expression of markers of late pro-B cells and pre-B cells and decreased immature B cells in bone marrow of Zfp521-deficient mice. As a mechanism that integrates the activities of both Zfp521 and EBF1, recent studies in our laboratory using newly developed antibody reagents detected Zfp521 binding to promoters that also bind EBF1. Co-occupancy of Zfp521 and EBF1 on these genes suggests a new model for co-regulation of B lymphopoiesis. In this manner, EBF1, the B lineage determination factor, is regulated by Zfp521 in developing B cells. Hypotheses: Zfp521 is critically important for B cell lymphopoiesis and function. We propose that it regulates the B cell program via EBF1-dependent and -independent mechanisms. Zfp521 interacts with EBF1 to limit its DNA binding, but Zfp521 also assembles complexes with EBF1 on target gene DNA. Determining the basis of interactions between EBF1 and Zfp521 at the molecular level is critical for understanding how the B cell regulatory network generates mature B cells capable of secreting antibodies in humoral immune responses. Therefore, we will: Determine how Zfp521 regulates gene transcription in developing B cells. Determine how Zfp521 functions in the B cell regulatory network by identifying its binding sites in pro- B cells. Define structural requirements and functional consequences of Zfp521 interactions with EBF1. PUBLIC HEALTH RELEVANCE: This project focuses on the functions of a novel nuclear protein, Zfp521, in B cell development and function. ZFp521 is required for the efficient production of antibody-producing B cells. Mice lacking Zfp521 have fewer B cells relative to normal mice. In part, Zfp521 functions by regulating EBF1, the B cell lineage determination/commitment factor. Zfp521 inhibits DNA binding by EBF1, but also binds DNA together with EBF1 in the context of chromatin in B cells. Zfp521 is a proto-oncogene that, when over-expressed, generates B cell leukemias and lymphomas, but little is known concerning these mechanisms.
描述(由申请人提供):骨髓中B细胞发育的概述是从多能造血干细胞(HSC)到定向未成熟B淋巴细胞的逐步过程。研究已经阐明了早期B细胞发育所必需的转录因子的B细胞特异性调节网络。这些蛋白质包括早期B细胞因子1(EBF 1),其驱动B谱系特化和定型。虽然对EBF 1了解很多,但关于其在B细胞中的调节及其蛋白质-蛋白质相互作用的潜力,仍有许多未解答的问题。有几条证据表明Zfp 521(Evi 3/ZNF 521/EHZF)是与EBF 1共同调控基因转录的因子。Zfp 521与EBF 1发生物理相互作用,并在体外抑制其活性。Zfp 521在发育中的B细胞中与EBF 1共表达。然而,关于Zfp 521在B细胞发育中的功能知之甚少。具体而言,Zfp 521调节EBF 1活性的机制以及Zfp 521和EBF 1之间物理相互作用的基础和后果尚不清楚。 我们已经证明,早期B细胞发育在Zfp 521不存在的情况下受到极大的干扰。这通过Zfp 521缺陷小鼠骨髓中晚期前B细胞和前B细胞的标志物表达的缺乏以及未成熟B细胞的减少来证明。作为一种整合Zfp 521和EBF 1活性的机制,我们实验室最近的研究使用新开发的抗体试剂检测到Zfp 521与也结合EBF 1的启动子结合。Zfp 521和EBF 1在这些基因上的共占据提示了B淋巴细胞生成的共调节的新模型。以这种方式,在发育中的B细胞中,B谱系决定因子EBF 1受Zfp 521调节。假设:Zfp 521对B细胞淋巴细胞生成和功能至关重要。我们认为它通过EBF 1依赖性和非依赖性机制调节B细胞程序。Zfp 521与EBF 1相互作用以限制其DNA结合,但Zfp 521也与靶基因DNA上的EBF 1组装复合物。在分子水平上确定EBF 1和Zfp 521之间相互作用的基础对于理解B细胞调控网络如何产生能够在体液免疫应答中分泌抗体的成熟B细胞至关重要。因此,我们将:确定Zfp 521如何调节发育中的B细胞的基因转录。通过鉴定前B细胞中Zfp 521的结合位点,确定Zfp 521在B细胞调控网络中的功能。定义Zfp 521与EBF 1相互作用的结构要求和功能后果。 公共卫生相关性:该项目的重点是一种新的核蛋白Zfp 521在B细胞发育和功能中的功能。ZFp 521是有效生产抗体生产B细胞所必需的。相对于正常小鼠,缺乏Zfp 521的小鼠具有较少的B细胞。Zfp 521部分地通过调节EBF 1(B细胞谱系决定/定型因子)起作用。Zfp 521抑制DNA与EBF 1的结合,但也在B细胞中的染色质环境中将DNA与EBF 1结合在一起。Zfp 521是一种原癌基因,当其过度表达时,会产生B细胞白血病和淋巴瘤,但关于这些机制知之甚少。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James R. Hagman其他文献

James R. Hagman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James R. Hagman', 18)}}的其他基金

Regulation of V(D)J Recombination by Arginine Methylation
精氨酸甲基化对 V(D)J 重组的调节
  • 批准号:
    9087092
  • 财政年份:
    2015
  • 资助金额:
    $ 40.73万
  • 项目类别:
Regulation of V(D)J Recombination by Arginine Methylation
精氨酸甲基化对 V(D)J 重组的调节
  • 批准号:
    8818975
  • 财政年份:
    2015
  • 资助金额:
    $ 40.73万
  • 项目类别:
Regulation of B Cell Development and Function by Zfp521
Zfp521 对 B 细胞发育和功能的调节
  • 批准号:
    9097469
  • 财政年份:
    2012
  • 资助金额:
    $ 40.73万
  • 项目类别:
Regulation of B Cell Development and Function by Zfp521
Zfp521 对 B 细胞发育和功能的调节
  • 批准号:
    8503596
  • 财政年份:
    2012
  • 资助金额:
    $ 40.73万
  • 项目类别:
Regulation of B Cell Development and Function by Zfp521
Zfp521 对 B 细胞发育和功能的调节
  • 批准号:
    8683097
  • 财政年份:
    2012
  • 资助金额:
    $ 40.73万
  • 项目类别:
Regulation of B Cell Identity and Lineage Progression
B 细胞身份和谱系进展的调节
  • 批准号:
    8212274
  • 财政年份:
    2010
  • 资助金额:
    $ 40.73万
  • 项目类别:
Regulation of B Cell Identity and Lineage Progression
B 细胞身份和谱系进展的调节
  • 批准号:
    8012293
  • 财政年份:
    2010
  • 资助金额:
    $ 40.73万
  • 项目类别:
Regulation of B Cell Identity and Lineage Progression
B 细胞身份和谱系进展的调节
  • 批准号:
    7917958
  • 财政年份:
    2010
  • 资助金额:
    $ 40.73万
  • 项目类别:
Regulation of B Cell Identity and Lineage Progression
B 细胞身份和谱系进展的调节
  • 批准号:
    8605152
  • 财政年份:
    2010
  • 资助金额:
    $ 40.73万
  • 项目类别:
Regulation of B Cell Identity and Lineage Progression
B 细胞身份和谱系进展的调节
  • 批准号:
    8420487
  • 财政年份:
    2010
  • 资助金额:
    $ 40.73万
  • 项目类别:

相似海外基金

Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    9981001
  • 财政年份:
    2017
  • 资助金额:
    $ 40.73万
  • 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    9751102
  • 财政年份:
    2017
  • 资助金额:
    $ 40.73万
  • 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    9397073
  • 财政年份:
    2017
  • 资助金额:
    $ 40.73万
  • 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    10223410
  • 财政年份:
    2017
  • 资助金额:
    $ 40.73万
  • 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-BETA (REBI
使用 SC IFN-β (REBI) 预防 MS 患者中和抗体形成
  • 批准号:
    7951676
  • 财政年份:
    2008
  • 资助金额:
    $ 40.73万
  • 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-β-AL
预防 SC IFN- 多发性硬化症患者中和抗体的形成
  • 批准号:
    7606036
  • 财政年份:
    2006
  • 资助金额:
    $ 40.73万
  • 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
  • 批准号:
    7375053
  • 财政年份:
    2005
  • 资助金额:
    $ 40.73万
  • 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
  • 批准号:
    7201220
  • 财政年份:
    2004
  • 资助金额:
    $ 40.73万
  • 项目类别:
Immunologic Mechanism of Inhibitor Antibody Formation in Hemophilia
血友病抑制剂抗体形成的免疫学机制
  • 批准号:
    6980810
  • 财政年份:
    2003
  • 资助金额:
    $ 40.73万
  • 项目类别:
INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE
血友病和冯·维勒布兰德病中的抑制剂抗体形成
  • 批准号:
    6419444
  • 财政年份:
    2000
  • 资助金额:
    $ 40.73万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了